Over the last 20 years, the treatment of cardiovascular diseases, withtheir high rate of serious endpoints, has been revolutionized byEvidence-based Medicine (EBM). Trailblazing developments include: the comeback of beta-blockers the towering significance of ACE inhibitors the effects of fibrinogen receptor antagonists.Moreover, only the rise of new adjunctive therapies has made it safetoperform percutaneous coronaryinterventions. Many answers have been found and rational conceptsdeveloped. But blind paths (e.g. in the positive inotropic andantiarrhythmic therapy) have come into focus as well.Numerous studies (e.g. ISIS, TIMI, GUSTO, GISSI) have systematically takenon the great issues confronting cardiology. Heart failure and even heartattacks have lost some of their fearsomeness. Life expectancy - thanks tothe combined administration of multiple medicines - has been prolongedsignificantly. Prevention continues to increase steadily in importance.In this comprehensive book on evidence-based cardiology, renowned experts describe and elucidate, what has proven to be ineffective, what has not yet been proven, but first and foremost, what - in terms of therapeutic progress - has been achieved by means ofrandomized studies with clinical endpoints.